Fri, Mar 6, 2015, 9:58 AM EST - U.S. Markets close in 6 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Piper Jaffray Companies Message Board

earningsbull 2 posts  |  Last Activity: Jan 26, 2015 9:55 AM Member since: Jan 3, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • they've decided to cover and I guess there is no reason for them to be on the board anymore.

  • We Remain Positive And Consistent With Our Bullish Investment Thesis On Achillion, Says Maxim

    December 22, 2014 10:02 PM EDT by Editor Jason Cohen in Analyst Insights • Healthcare

    In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, as the company announced positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422.

    Kolbert noted, “Gilead’s Sovaldi plus Achillion’s NS5A (ACHN-3102) showed “best in class” data, 100% SVR4 in a six week trial. Data from the second trial showed Achillion’s Nucleoside to be potent with a differentiated mechanism of action.”

    The analyst added, “Looks like Achillion has a viable nucleoside and we know they have a viable NS5A (probably best in class), together they equal High SVR’s with short treatment duration. With end of year cash ~$100M, we remain positive and consistent with our very bullish investment thesis.”

    Sentiment: Strong Buy

54.73+0.77(+1.43%)9:51 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.